ADVERSE EVENTS OF NEW AEDS. LIONEL CARMANT, MD Professor of Neurosciences and Pediatrics
|
|
- Raymond Chapman
- 5 years ago
- Views:
Transcription
1 ADVERSE EVENTS OF NEW AEDS LIONEL CARMANT, MD Professor of Neurosciences and Pediatrics
2 DISCLOSURE Lionel Carmant: Grants/Research projects: Mettrum/ Zogenix Speakers bureau: UCB, Eisai, Lina Nova Off label use of Rufinamide
3 INTRODUCTION BRIVARACETAM PERAMPANEL RUFINAMIDE ESLICARBAZEPINE CBD FENFLURAMINE CONCLUSIONS OVERVIEW
4 INTRODUCTION It is unclear whether the rapid development of new AEDs has actually reduced the number of drug resistant epilepsy patients So the next goal to improve quality of life for these patients is to reduce the number of treatment-emergent adverse events This could lead to rationale polytherapy being eventually reality
5 BRIVARACETAM
6 Discovery of Brivaracetam Discovered from a rational drug discovery screening project of racetam derivatives for selective, high-affinity SV2A ligands ~12,000 compounds screened for in vitro interaction with SV2A 1 ~ 900 compounds tested for in vivo activity against audiogenic seizures in mice 1 ~ 30 compounds profiled in a broad range of animal models of seizures and epilepsy 1 Levetiracetam FAMILY LEV-like animal model seizure protection profile 1,2a Inactive in MES and PTZ models 1 Brivaracetam FAMILY LEV non-like animal model seizure protection profile 1 Active in MES and PTZ models 1 The clinical relevance of these findings is unknown a Animal model seizure protection profile is the range of rodent models that all compounds were tested in. LEV=levetiracetam; MES=maximal electroshock; PTZ=pentylenetetrazole; SV2A=synaptic vesicle protein 2A. 1. Matagne A, et al. Br J Pharmacol. 2008;154: ; 2. Klitgaard H, et al. Eur J Pharmacol. 1998;353:
7 BRIVARACETAM CLINICAL TRIALS 3 pivotal studies: N01252, N01253, and N01358 % PBO (n=459) BRV 50 mg/day (n=200) BRV 100 mg/day (n=353) BRV 200 mg/day (n=250) BRV Combined (n=803) At least 1 TEAE TEAEs leading to study drug discontinuation Drug-related TEAEs Severe TEAEs Serious TEAEs Deaths BRV=brivaracetam; PBO=placebo; TEAE=treatment-emergent adverse event. Quarato PP, et al. Presented at the 31st International Epilepsy Congress (IEC): September 5-9, 2015; Istanbul, Turkey. Poster P0851.
8 BRIVARACETAM Most frequent behavioural AE: Irritability (3.2%) Aggression (0.5%) Agitation (0.5%) Anger (0.2%) Leading to treatment discontinuation (0.9%)
9 BRIVARACETAM Key results 27/29 (93.1%) patients had physician-assessed clinically meaningful reduction in BAEs at end of treatment (primary safety analysis); no worsening in intensity was reported 18/29 (62.1%) patients had complete abatement from primary BAEs; median time to primary BAE resolution was 15 days after the first BRV dose Intensity of BAEs at baseline, % Intensity of BAEs at end of treatment period, % Resolved Mild Moderate Severe Mild Moderate Severe Total BAEs=behavioral adverse events; BRV=brivaracetam; LEV=levetiracetam. Yates SL, et al. Epilepsy Behav. 2015;52:
10 Experimental data Sanon et al. manuscript in preparation
11 Summary Table Sanon et al. manuscript submitted
12 Resident Intruder test: aggressive and social behaviors are affected by LEV, not BRV Sanon et al. manuscript in prep
13 PERAMPANEL
14 PERAMPANEL
15 PERAMPANEL Blockade of AMPA receptors will alter fast synaptic transmission 3 pivotal studies: Perampanel Placebo (N=442) 2 mg (N=180) 4 mg (N=172) 8 mg (N=431) 12 mg (N=255) Subjects with any TEAE Dizziness Somnolence Headache Fatigue Irritability Fall Nausea Nasopharyngitis Upper respiratory tract infection Ataxia Balance disorder
16 Alertness / Cognition-Related TEAEs Placebo (n=82) Perampanel (n=81) Patients with any TEAE (narrow and broad SMQ terms) 12 (14.6) 16 (19.8) Somnolence 3 (3.7) 9 (11.1) Hallucination 2 (2.4) 2 (2.5) Mood swings 0 (0.0) 2 (2.5) Mood altered 2 (2.4) 1 (1.2) Abnormal behavior 2 (2.4) 1 (1.2) Affect lability 0 (0.0) 1 (1.2) Aggression 0 (0.0) 1 (1.2) Aphasia 0 (0.0) 1 (1.2) Delusion 0 (0.0) 1 (1.2) Hallucination, visual 0 (0.0) 1 (1.2) Illusion 0 (0.0) 1 (1.2) Speech disorder 0 (0.0) 1 (1.2) Confusional state 2 (2.4) 0 (0.0) Hallucination, auditory 1 (1.2) 0 (0.0) Initial insomnia 1 (1.2) 0 (0.0) All values are n (%).
17 Psychosis / Psychotic Disorder-Related TEAEs Placebo (n=82) Perampanel (n=81) Patients with any TEAE (narrow and broad SMQ terms) 3 (3.7) 6 (7.4) Hallucination a 2 (2.4) 2 (2.5) Abnormal behavior b 0 (0.0) 1 (1.2) Affect lability b 0 (0.0) 1 (1.2) Delusion a 0 (0.0) 1 (1.2) Hallucination, visual a 0 (0.0) 1 (1.2) Illusion a 0 (0.0) 1 (1.2) Paranoia a 0 (0.0) 1 (1.2) Speech disorder b 0 (0.0) 1 (1.2) Hallucination, auditory a 1 (1.2) 0 (0.0) No TEAEs were considered serious 1 patient in the perampanel group discontinued treatment due to abnormal behavior (severe and treatment-related; resolved after 1 day) a Narrow SMQ term; b broad SMQ term. All values are n (%).
18 PERAMPANEL Treatment-emergent SAEs occurred in 6 (7.4%) patients receiving perampanel vs 7 (8.5%) patients in the placebo group Discontinuation due to TEAEs occurred in 9 (11.1%) patients receiving perampanel and 5 (6.1%) patients in the placebo group Dose reductions related to TEAEs occurred in 8 (9.9%) patients receiving perampanel and 6 (7.3%) patients in the placebo group Dose interruption or reduction occurred at 8-12 mg per day.
19 RUFINAMIDE
20 Bialer & White, Nat Rev Drug Disc 2010
21 RUFINAMIDE Studied in children/adults with LGS (90 sz/mo) 2 pivotal studies: 022E and % AE with most frequent Somnolence (33.8%) Vomiting (21.6%) Decreased appetite (9.5%)
22 RUFINAMIDE SAE rare, similar to placebo <1% Risk of increased major seizure frequency (20.8%)
23 RUFINAMIDE Post marketing data For LGS 12 studies 23-71% AEs Drowsiness/Fatigue and GI symptoms Non LGS 17 studies 24-96% (most in the 20-40%) Dizziness and fatigue most common Go slow, stay low!
24 ESLICARBAZEPINE
25 ESLICARBAZEPINE First approved in Europe in Pivotal studies Special studies in >65 y.o.; hepatic and renal impairment Frequent (>10%) TEAE: Dizziness, somnolence, headache and nausea Dose dependent
26 ESLICARBAZEPINE SAE: Not dose dependent 1.2% Post-marketing studies: hyponatremia (10.2%) seizure (5.8%) dizziness (4.1%) Sperling M. et al., 2015
27 ESLICARBAZEPINE Sperling M. et al., 2015
28 ESLICARBAZEPINE
29 FENFLURAMINE
30 FENFLURAMINE 1981 by Douglas et al.: 2 women with symptoms of pulmonary hypertension, including exertional breathlessness and exercise intolerance, while taking fenfluramine at doses of 120 or 160mg/day. Case-control study: 95 patients with PPH compared with a cohort of 355 control patients matched for age and gender The use of dexfenfluramine or fenfluramine, was higher in the case patients (31.6%) compared with the controls (7.3%; adjusted odds ratio for the risk of PPH = 6.3, 95% CI = ). The use for periods >3 months was associated with an odds ratio of 23.1 (95% CI ).
31 FENFLURAMINE Incidence of at least 1 TEAE: 95% (n=38) of patients in the 0.8mg/kg/day group 94.9% (n=37) of patients in the 0.2 mg/kg/day 65.0% (n=26) of patients in the placebo group. Incidence of SAEs: 12.5% (n=5) of patients in the 0.8 mg/kg/day group 10.3% (n=4) of patients in the 0.2 mg/kg/day group 10.0% (n=4) of patients in the placebo group. AEs leading to discontinuation: Five patients in the 0.8 mg/kg/day group None in the other treatment groups.
32 CBD/THC
33 CBD
34 CBD 100 mg/ml of CBD 5, 10 and 20 mg/kg AE reported in 93% vs 75% SAE in 10 vs 3 children Withdrawal from trial 8 vs 1 child
35 CBD
36 CBD Care-E study: Pharmacokinetic study Efficacy study Small number of patients Quebec registry: 32 children and opening to other centres Goal is to study Canadian products: THC- other compounds Open label study to enable physicians to prescribe in a research protocol Looking to recruit 300 children
37 CBD In our experience: Lower doses than epidiolex are needed to see effect Somnolence is common, interaction with clobazam Tolerance can be seen Dose dependent increase in seizure frequency
38 CONCLUSIONS Systemic AEs are rare with new molecules but CNS still common Knowledge of drug specific AEs is required Rationale polytherapy for Dravet syndrome: CLB- STP- Fenfluramine With growing list of available seizure medication, early referral to Epilepsy Centre is becoming more and more important
New AEDs in Uncontrolled seizures
New AEDs in Uncontrolled seizures Uncontrolled seizures/epilepsy Intractable epilepsy, Refractory epilepsy, Pharmacoresistant epilepsy Dr. Suthida Yenjun Traditionally, referred to therapeutic failure
More informationNewer AEDs compared to LVT as adjunctive treatments for uncontrolled focal epilepsy. Dr. Yotin Chinvarun. M.D. Ph.D.
Newer AEDs compared to LVT as adjunctive treatments for uncontrolled focal epilepsy Dr. Yotin Chinvarun. M.D. Ph.D. Chronology of antiepileptic drug introduction over the past 150 years 20 15 10 Perampanel
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More information2 nd Line Treatments for Dravet. Eric BJ Ségal, MD Northeast Regional Epilepsy Group
2 nd Line Treatments for Dravet Eric BJ Ségal, MD Northeast Regional Epilepsy Group Disclosures Accepted honoraria from Greenwich Pharmaceuticals, Zogenix, Eisai, Lundbeck, Lineagen. Overview Evidence
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
December 7, 2015 GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy As previously announced, seven posters
More informationNew Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous]
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSeizure medications An overview
Seizure medications An overview Andrew Zillgitt, DO Staff Neurologist Comprehensive Epilepsy Center Department of Neurology Henry Ford Hospital None Disclosures Objectives A lot to review!!!!! Look at
More informationPerampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings
Accepted: 13 November 2017 DOI: 10.1111/ane.12879 REVIEW ARTICLE Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings J.-J. Tsai 1 T. Wu 2 H. Leung 3 T. Desudchit
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationErnie Somerville Prince of Wales Hospital EPILEPSY
Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist
More informationEpilepsy Medications: The Basics
Epilepsy Medications: The Basics B R I A N A P P A V U, M D C L I N I C A L A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F C H I L D H E A L T H A N D N E U R O L O G Y, U N I V E R S I T
More informationWARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS See full prescribing information for complete boxed warning.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FYCOMPA safely and effectively. See full prescribing information for FYCOMPA. FYCOMPA (perampanel)
More informationI M DETERMINED to find a different option to treat my seizures
APPROVED FOR CHILDREN with epilepsy 4 years of age and older with partial-onset seizures I M DETERMINED to find a different option to treat my seizures What is FYCOMPA (perampanel)? FYCOMPA is a prescription
More informationKEPPRA (levetiracetam) injection, for intravenous use Initial U.S. Approval: 1999
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (levetiracetam) injection, for intravenous
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
DISCLAIMER All labeling reflected on this website is for informational and promotional purposes only. It is not intended to be used by healthcare professionals or patients for the purpose of prescribing
More informationFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE
451158D/Revised: July 2015 Injection, USP HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEVETIRACETAM INJECTION, USP safely and effectively. See
More informationEpidiolex (cannabidiol) NEW PRODUCT SLIDESHOW
Epidiolex (cannabidiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Epidiolex Generic name: Cannabidiol Pharmacological class: Cannabinoid Strength and Formulation: 100mg/mL; oral soln; strawberry-flavored;
More informationCONTRAINDICATIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEPPRA safely and effectively. See full prescribing information for KEPPRA. KEPPRA (levetiracetam)
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the
More informationChantix Label Update 2018
Chantix Label Update 2018 Chantix (varenicline) Prescribing Information Chantix Prescribing Info URL and Disclaimer Please refer to the full Prescribing Information on important treatment considerations
More informationThis is a duplicated text of a letter from GW Pharma Ltd. Contact the company for a copy of any references, attachments or enclosures.
Health Canada posts safety alerts, public health advisories, press releases and other notices from industry as a service to health professionals, consumers and other interested parties. Although Health
More information13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 5.3 Somnolence and Fatigue
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEVETIRACETAM safely and effectively. See full prescribing information for LEVETIRACETAM. LEVETIRACETAM
More informationKEPPRA (levetiracetam) tablets, for oral use KEPPRA (levetiracetam) oral solution Initial U.S. Approval: 1999
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEPPRA safely and effectively. See full prescribing information for KEPPRA. KEPPRA (levetiracetam)
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLEVETIRACETAM extended-release tablets, for oral use Initial U.S. Approval: 1999
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEVETIRACETAM EXTENDED RELEASE TABLETS safely and effectively. See full prescribing information for
More informationNewer Anticonvulsants: Targets and Toxicity. Laura Tormoehlen, MD Neurology and EM-Toxicology
Newer Anticonvulsants: Targets and Toxicity Laura Tormoehlen, MD Neurology and EM-Toxicology Disclosures No financial disclosures DEFINITIONS Objectives/Outline Mechanism of Action Specific Indications
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use levetiracetam extended-release tablets safely and effectively. See full prescribing information for
More informationNo May 25, Eisai Co., Ltd.
No.16-35 May 25, 2016 Eisai Co., Ltd. EISAI TO LAUNCH IN-HOUSE DEVELOPED ANTIEPILEPTIC DRUG FYCOMPA (PERAMPANEL HYDRATE) AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES IN
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationLasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine
(200 mg and 100 mg) Compared to for Acute Treatment of Migraine Bernice Kuca, M.S. 1 ; Linda A. Wietecha, B.S.N., M.S. 2 ; Paul H. Berg, M.S. 2 ; Sheena K. Aurora, M.D. 2 1 CoLucid Pharmaceuticals, Inc.,
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOnfi (clobazam) Labeled Uses: Clobazam is used as adjuvant treatment of seizures from Lennox-Gastaut Syndrome. 1,2
Onfi (clobazam) Brand Name: Onfi Generic Name: clobazam Manufacturer: Lundbeck Inc. Drug Class: Benzodiazepine Labeled Uses: Clobazam is used as adjuvant treatment of seizures from Lennox-Gastaut Syndrome.
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1078-11 Program Prior Authorization/Notification - Anticonvulsants Medication Aptiom (eslicarbazepine acetate); Banzel (rufinamide);
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationTo report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at (844) 599-CARE (2273) or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEPPRA XR safely and effectively. See full prescribing information for KEPPRA XR. KEPPRA XR (levetiracetam)
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1078-10 Program Prior Authorization/Notification - Anticonvulsants Medication Aptiom (eslicarbazepine acetate); Banzel (rufinamide);
More informationAED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology
AED Treatment Approaches David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology Audience Response Keypads Please utilize the keypad at your table to answer questions throughout
More informationSMOKING CESSATION IS HARD
POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationLondon, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION
London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.
More informationTransdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS)
Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS) H. Heussler, MD; J. Cohen, MD; N. Silove, MD; N. Tich, PhD; C. O Neill; and M. Bonn-Miller, PhD Liza A. Squires, MD Chief
More informationInvestigational Pharmacy Cannabidiol treatment in Epilepsy
Jon Beck BS Pharm D Coordinator Investigational Pharmacy Disclosure I have no relevant financial relationships with a Commercial Provider Nebraska Medicine Omaha, NE Investigational Pharmacy Cannabidiol
More informationPage 1 of 33. LEVETIRACETAM extended-release tablets, for oral use Initial U.S. Approval: 1999
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEVETIRACETAM EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for
More informationand 50cP; polydextrose FCC; polyethylene glycol 800; titanium dioxide; and triacetin.
LEVETIRACETAM - levetiracetam tablet, film coated Solco Healthecare US, LLC DESCRIPTION is an antiepileptic drug available as 250 mg (pink), 500 mg (pink), 750 mg (pink), and 1000 mg (white) tablets for
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationSafety, Tolerability and Target Engagement Demonstrated in Phase 1 Study of LRRK2 Inhibitor DNL201 in Healthy Young and Elderly Adults
Safety, Tolerability and Target Engagement Demonstrated in Phase 1 Study of LRRK2 Inhibitor DNL201 in Healthy Young and Elderly Adults MJFF Parkinson s Disease Therapeutics Conference October 25, 2018
More informationPage 1 of 16. KEPPRA (levetiracetam) Injection for Intravenous Use Initial U.S. Approval: 1999
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use injection safely and effectively. See full prescribing information for injection. (levetiracetam)
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEVETIRACETAM TABLETS USP safely and effectively. See full prescribing information for LEVETIRACETAM
More informationAcknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making
Cannabis Evidence Series What it is What it s not Acknowledgements: The evidence presented is from the Cannabis evidence series authored by the HTA unit at the University of Calgary and from Rapid response
More informationNew Medications in Early Psychosis
New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Yes Yes Yes Epocrates Research Contract Royalties Yes Stock Janssen
More information7/31/09. New AEDs. AEDs. Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital. 1 st genera*on AEDs
Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital New AEDs AEDs NEW OLD Pregabalin Pregabalin 1 st genera*on AEDs Phenytoin Carbamazepine Valproate Phenobarbital
More informationSee Through The Masquerade To Avoid Paying Twice
See Through The Masquerade To Avoid Paying Twice Vladimir Bokarius, MD, PhD, QME CWCDAA Conference, October, 2018 Las Vegas, NV Agenda Mental Health Mental or Medical? Mental Health Disorders Due to General
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLEVEPSY Tablets (Levetiracetam)
Published on: 23 Feb 2016 LEVEPSY Tablets (Levetiracetam) Composition LEVEPSY 250 Tablets Each film-coated tablet contains Levetiracetam 250 mg LEVEPSY 500 Tablets Each film-coated tablet contains Levetiracetam
More informationKEPPRA (levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg tablets 100 mg/ml oral solution DESCRIPTION
KEPPRA (levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg tablets 100 mg/ml oral solution Rx only DESCRIPTION KEPPRA is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow), 750 mg (orange),
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationPRODUCT MONOGRAPH. Pr FYCOMPA. Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg Tablets. Perampanel Oral Suspension 0.
PRODUCT MONOGRAPH Pr FYCOMPA Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg Tablets Perampanel Oral Suspension 0.5 mg/ml suspension Professed Standard Antiepileptic Agent Eisai Limited 6925
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER 250 mg film-coated tablets. 500 mg film-coated tablets. 750 mg film-coated tablets. 1000 mg film-coated tablets. Levetiracetam
More informationUCB reinforces commitment to epilepsy community on European Epilepsy Day
For the attention of accredited medical and business writers UCB reinforces commitment to epilepsy community on European Epilepsy Day Marking 100,000 patients treated milestone for Vimpat (lacosamide)
More informationThe National Methamphetamine Symposium
The National Methamphetamine Symposium Making Research Work in Practice 12 May 2015 Arts Centre, Melbourne Physical and psychological effects of methamphetamine use Amanda Baker PhD National Centre for
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationAn overview of reports on lacosamide
An overview of reports on lacosamide Introduction Lacosamide (Vimpat ) was registered for the European market on August 29th 2008. Since then Lareb has received several reports of possible adverse drug
More informationCANNABIDIOL (CBD) THE BE ALL END ALL?
CANNABIDIOL (CBD) THE BE ALL END ALL? John Schaeffer, DO PMG neurology specialists Clinical associate professor Department of neurology University of Washington school of medicine CANNABIS BRIEF HISTORY
More informationPRODUCT MONOGRAPH. Pr FYCOMPA. Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg Tablets. Perampanel Oral Suspension 0.
PRODUCT MONOGRAPH Pr FYCOMPA Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg Tablets Perampanel Oral Suspension 0.5 mg/ml suspension Professed Standard Antiepileptic Agent Eisai Limited 6925
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationCannabis and cannabinoids for medicinal purposes
Cannabis and cannabinoids for medicinal purposes International Evidence and Evidence for Practice in Australia Michael Farrell Louisa Degenhardt, Wayne Hall, Nicholas Buckley, Megan Weir, Suzi Neilsen,
More informationsodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission sodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd 10 August 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationFULL-LENGTH ORIGINAL RESEARCH SUMMARY. * Patrick Kwan, Eugen Trinka, Wim Van Paesschen, Ivan Rektor, #Martin E. Johnson, and **Sarah Lu
FULL-LENGTH ORIGINAL RESEARCH Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial * Patrick
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationDr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 262 Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina)
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING
FOR IMMEDIATE RELEASE IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING George Town, Cayman Islands January 10, 2019 Ironshore
More informationOverview of Psychoactive Drug use
Overview of Psychoactive Drug use By Dr. Oladosu Ahmed Kayode Specialist in mental health Attending physician Dept. of psychiatry, GH Ilorin & Hopeville Psychiatric Hospital, Ilorin. Learning objectives
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationRefractory epilepsy: treatment with new antiepileptic drugs
Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN 2 RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERISE THE RISKS
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for Briviact This is a summary of the risk management plan (RMP) for Briviact. The RMP details important risks of Briviact,
More informationCAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections
CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More informationEpilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
More informationAnne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2
Peripheral Edema and Weight Gain in Adult Patients With Painful Diabetic Peripheral Neuropathy Receiving Gabapentin Enacarbil or Pregabalin Enrolled in a Randomized, Phase 2 Trial Anne M. Calkins, 1 Joseph
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More information